Novo Nordisk A/S NVO reported second-quarter 2025 earnings of 97 cents per American Depositary Receipt (ADR), which beat the Zacks Consensus Estimate of 93 cents. The company had reported earnings of ...

Share on Twitter Print Share by Email Share Back to top In spring 2025, the Food and Drug Administration (FDA) resolved and ended the ...

GLP-1 agonists -- which include blockbusters such as semaglutide (Rybelsus, Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) -- were initially approved for type 2 diabetes before gaining ...

As of 2024, Medicare Part D covers Ozempic, Mounjaro, Rybelsus (semaglutide), and Wegovy for FDA-approved conditions. But they are not covered for weight loss.

Learn more about how to get Ozempic, including who can take it and where to find it, plus cost issues and the latest safety concerns to know about.